Librela vs. Meloxicam: The Showdown No One Asked For, But Everyone Has Opinions About
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Librela vs. Meloxicam: The Showdown No One Asked For, But Everyone Has Opinions About
-
ナレーター：
-
著者：
概要
In this episode of Whiskers & Wisdom, we dive into the veterinary Facebook feud of the decade: Librela vs. Meloxicam.
No drama. No fearmongering. No “my neighbor’s cousin’s dog’s groomer said…” energy.
Just real science, real data, and real physiology — explained in a way that won’t make you want to walk into Lake Michigan and become a mermaid.
We break down a 2025 randomized, controlled clinical trial comparing Librela (the NGF‑targeting monoclonal antibody) to meloxicam (the classic NSAID), and we talk about what the study actually found:
- •Both treatments helped
- •Librela had fewer adverse events in this specific group of dogs
- •Older, fragile dogs tolerated Librela well
- •Compliance matters more than we think
- •And no, this study does not say Librela is magic or meloxicam is obsolete
Pain is personal. Osteoarthritis is complex. And dogs are individuals, not algorithms.
If you want to read the study yourself, the link is in the show notes.
https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1502218/full